Treatment of drug-resistant tuberculosis.
D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003523:Cycloserine / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology; D004342:Drug Hypersensitivity; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced; D007538:Isoniazid / Q000627:therapeutic use; D007612:Kanamycin / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D011718:Pyrazinamide / Q000627:therapeutic use; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000601:surgery; D014756:Viomycin / Q000627:therapeutic use
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D011718:Pyrazinamide; D007612:Kanamycin; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin; D014756:Viomycin